Oct. 10, 2025, is officially the first-ever National PrEP Day, and MISTR and SISTR are going big. Their goal? Get 10,000 new ...

The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir ...

Avoidable HIV infections and net health care costs would rise if coverage of pre-exposure prophylaxis (PrEP) were to be reduced even a moderate amount, according to a study published in JAMA Network ...

Friday marks the 35th anniversary of World AIDS Day, an international moment to remember, reflect and educate people on the HIV/AIDS epidemic that started over four decades ago. But due to ...

HIV (human immunodeficiency virus) remains a significant global health challenge, affecting millions of people worldwide. While advancements in medical science have led to better management of the ...

In his first term, President Trump pledged to boost HIV spending, with the lofty goal of bringing the epidemic to heel by ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

A new study found that adults in custody of the Federal Bureau of Prisons have seen improved pre-exposure prophylaxis (PrEP) initiation and sustained treatment uptake for HIV. Rates of HIV ...

Gilead's groundbreaking HIV prevention drug will soon be available at a fraction of its U.S. price in over 100 countries, ...

Most transfeminine people support OTC access to PrEP for HIV prevention as means to eliminate burden and costs of clinical visits and laboratory testing.

Pre-exposure prophylaxis (PrEP) is a medication regimen that is used to protect at-risk populations from HIV infection. The FDA approved the drug TRUVADA ...